MedPath

Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease

Conditions
Byler Disease
Registration Number
NCT01949766
Lead Sponsor
University of Pittsburgh
Brief Summary

This is a single patient compassionate use protocol to determine whether RAVICTI will improve bile flow in a subject who previously tolerated therapy with Buphenyl.

Detailed Description

Not available

Recruitment & Eligibility

Status
NO_LONGER_AVAILABLE
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Byler Disease
  • Cholestasis
  • Tolerance of Buphenyl therapy
Read More
Exclusion Criteria
  • Allergy/Hypersensitivity to RAVICTI
Read More

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath